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Vascular Smooth Muscle Enhances Functionality of
Tissue Engineered Blood Vessels In Vivo
Lucas P. Neff1, Bryan Tillman1, Saami Yazadani2, Masood
Machingal2, James Yoo2, Shay Soker2, Brian Bernish1, Ran-
dolph Geary1, George Christ2. 1Vascular Surgery, Wake
Forest University School of Medicine, Winston-Salem,
NC; 2Wake Forest Institute of Regenerative Medicine,
Winston-Salem, NC
Objectives: Physiologic responses of tissue engineered
blood vessels (TEBV) seeded with endothelial cells (EC)
remains suboptimal compared to native arteries due to lack
of smooth muscle cells (SMC) in the vessel media. Thus,
there may be benefit to incorporating SMCs into TEBV. In
vitro studies have shown limited vasomotor activity in SMC
seeded TEBV. The goal of the present study was to evaluate
the impact of SMC co-seeding on TEBV structure and
function after prolonged in vivo maturation.
Methods: DsTEBV TEBV (dsTEBV) were created
co-seeding autologous ECs derived from circulating pro-
genitor cells (EPC) and SMCs from artery explants onto
lumen and outer surface of extracellular matrix (ECM)
scaffolds, respectively. Controls were seeded with EC alone
(ecTEBV). All vessels were pre-conditioned to pulsatile
flow for 10-14 days in a bioreactor, implanted as arterial
interposition grafts in sheep, and allowed to heal and adapt
in vivo for 4 months before ex vivo physiological testing
and histological analysis.
Results: Five vessels were implanted in each group and all
were patent at 4 months. There were no structural failures,
aneurysms, or infectious complications. dsTEB vs exhibited a
greater degree of wall maturation characterized by higher
medial cellularity (p 0.01) and greater percentage of-actin
(p  0.005) and SMC-specific muscle myosin heavy chain
(sm-MHC, p  0.005) staining compared to ecTEB vs.
Vasomotor responses in hung rings of dsTEBV showed sig-
nificantlymore contraction in response to phenylephrine (p
0.01) and serotonin (p 0.01) than ecTEBV.
Conclusions: This is the first study to demonstrate
enhanced in vivo wall maturation and development of
contractile function when bioengineered vessels are co-
seeded with autologous SMC and EC compared to EC
seeding alone. These data suggest a co-seeding strategy can
be accomplished in a clinically relevant time frame (typically
6 weeks) and may prove superior for arterial reconstruction
compared to vessels engineered only with endothelium.
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SS2.
Evolution of Operative Strategies in Open Thoracoab-
dominal Aneurysm Repair (TAA)
Richard P. Cambria, Mark F. Conrad, Emel A. Ergul,
Virendra I. Patel, GlennM. LaMuraglia, Matthew R. Cam-
bria. Vascular Surgery, Massachusetts General Hospital,
Boston, MA
Objectives: Over a 24-year interval we managed most
(90%) of thoracoabdominal aortic aneurysms (TAA) with
a clamp and sew (CS) approach with protective adjuncts of
epidural cooling and aggressive intercostal reconstruction
(IC) to prevent spinal cord ischemia. A finite death/para-
plegia rate led to modifications using distal aortic perfusion
(DAP) via atriofemoral bypass to support cord collateral
circulation and selective IC based on motor evoked poten-
tial (MEP) monitoring. This study evaluates the early im-
pact of DAP on TAA outcomes.
Methods: Consecutive patients undergoing repair of
nonruptured Crawford extent I-III TAA using DAP/MEP
were compared to a propensity-matched cohort of patients
treated with CS. Outcomes include 30-day mortality and
paraplegia.
Results: There were 52 patients in the DAP cohort vs
127 undergoingCS. The cohorts differed in age (62.6 years
vs 69.5 years CS, p  0.0003), presence of Marfan’s (10%
DAP vs 2% CS, p  0.01), and chronic dissection (37%
DAP vs 8% CS, p  0.001). Mortality was low in both
groups (2% vs 5% CS, p  0.38); postoperative renal
insufficiency, albeit doubled in CS, was not significant (8%
DAP vs 17% CS, p  0.10). DAP had a significantly lower
incidence of IC than the CS group (10% DAP vs 34% CS,
p 0.0001), yet there was no paraplegia in the DAP cohort
(0% DAP vs 5% CS, p  0.11). The composite death/
paraplegia rate was decreased with DAP (1/52 (2%) DAP
vs 11/127 (9%) CS, p  0.01). Paraparesis with complete
recovery occurred in 5/52 (10%) of the DAP group.
Conclusions: Elective TAA repair was accomplished
with a low mortality in both the DAP and CS cohorts. The
use of MEP in the DAP cohort (despite higher risk because
of number of chronic dissections) decreased the need for IC
with no paraplegia to date. DAP with MEP is the preferred
operative strategy for TAA repair.
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